Last reviewed · How we verify

NCT06383195

The Reliability and Validity of the Ankylosing Spondylitis Performance Index (ASPI) in Enthesitis-Related Arthritis

Recruiting now Last updated 25 April 2024
What this trial tests

trial in Enthesitis Related Arthritis in 40 participants. Currently enrolling.

Timeline
21 March 2024
Primary endpoint
20 March 2026
20 March 2026

Quick facts

Lead sponsorHacettepe University
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment40
Start date21 March 2024
Primary completion20 March 2026
Estimated completion20 March 2026
Sites1 location across Turkey (Türkiye)

Conditions studied

Sponsor

Hacettepe University

Who can join

Adults 7 to 18, any sex, with Enthesitis Related Arthritis or Enthesitis Related Arthritis, Juvenile. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study assesses the test-retest reliability, construct validity, and minimal detectable change of the Ankylosing Spondylitis Performance Index (ASPI) in assessing the physical function of patients with Enthesitis-related arthritis (ERA).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Proceedings of the 32nd European Paediatric Rheumatology Congress.
    · 2025 · cited 1× · PMID 40958115 · DOI 10.1186/s12969-025-01138-8

Verify or expand the search:

Other Hacettepe University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06383195.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing